/ELYM
ELYM Stock - Eliem Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$5.11-0.97%
$0.05 (-0.97%) • Oct 2
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.28
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $5.62
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ELYM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.06 – $5.16
TARGET (TP)$5.88
STOP LOSS$4.70
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.38
52W High$11.55
52W Low$2.35
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-82,020,000 | $-21,466,000 | $-45,135,000 | $-35,672,000 | $-20,925,000 |
| Net Income | $-73,897,000 | $-35,119,000 | $-45,353,000 | $-47,480,000 | $-11,510,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.53 | $-1.30 | $-1.72 | $-1.81 | $-0.44 |
Company Overview
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ELYMBeat Rate
45%
Last 11 quarters
Avg Surprise
-14.8%
EPS vs Estimate
Beats / Misses
5/5
1 met exactly
Latest EPS
$-0.15
Q4 2024
EPS Surprise History
Q1 23
+34.1%
$-0.29vs$-0.44
Q2 23
-200.0%
$-0.84vs$-0.28
Q3 23
-18.8%
$-0.19vs$-0.16
Q4 23
-7.1%
$-0.15vs$-0.14
Q1 24
0.0%
$-0.13vs$-0.13
Q2 24
No data
Q3 24
No data
Q4 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Nov 12, 2024 | — | $-0.15 | — | — |
Q3 2024 | Aug 14, 2024 | — | $-1.81 | — | — |
Q2 2024 | May 15, 2024 | — | $-0.06 | — | — |
Q1 2024 | Mar 28, 2024 | $-0.13 | $-0.13 | 0.0% | = MET |
Q4 2023 | Nov 14, 2023 | $-0.14 | $-0.15 | -7.1% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.16 | $-0.19 | -18.8% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.28 | $-0.84 | -200.0% | ✗ MISS |
Q1 2023 | Mar 6, 2023 | $-0.44 | $-0.29 | +34.1% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.42 | $-0.37 | +11.9% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.47 | $-0.52 | -10.6% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.57 | $-0.50 | +12.3% | ✓ BEAT |
Q1 2022 | Mar 7, 2022 | $-0.70 | $-0.40 | +42.9% | ✓ BEAT |
Q4 2021 | Nov 8, 2021 | $-1.17 | $-0.70 | +40.2% | ✓ BEAT |
Q3 2021 | Sep 13, 2021 | $-1.86 | $-3.11 | -67.2% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | — | $-1.60 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-1.27 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.19 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.14 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.16 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ELYM
What is ELYM's current stock price?
Eliem Therapeutics, Inc. (ELYM) is currently trading at $5.11 per share. The stock has moved -0.97% today.
What is the analyst price target for ELYM?
No analyst price targets are currently available for this stock.
What sector is Eliem Therapeutics, Inc. in?
Eliem Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ELYM's market cap?
Eliem Therapeutics, Inc. has a market capitalization of $0.34 billion, making it a small-cap company.
Does ELYM pay dividends?
No, Eliem Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCKPT
Checkpoint Therapeutics, Inc.
$4.26
Mkt Cap: $0.4B
GTHX
G1 Therapeutics, Inc.
$7.16
Mkt Cap: $0.4B
INZY
Inozyme Pharma, Inc.
$4.00
Mkt Cap: $0.3B
ITOS
iTeos Therapeutics, Inc.
$10.15
Mkt Cap: $0.4B
ORTX
Orchard Therapeutics plc
$16.70
Mkt Cap: $0.4B
RVNC
Revance Therapeutics, Inc.
$3.65
Mkt Cap: $0.4B
SCPH
scPharmaceuticals Inc.
$5.67
Mkt Cap: $0.3B
TCRT
Alaunos Therapeutics, Inc.
$3.56
Mkt Cap: $0.0B
VIGL
Vigil Neuroscience, Inc.
$8.05
Mkt Cap: $0.4B
YMAB
Y-mAbs Therapeutics, Inc.
$8.61
Mkt Cap: $0.4B
Explore stocks similar to ELYM for comparison